(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.28%) $79.17
(0.00%) $2.04
(0.16%) $2 313.20
(0.36%) $26.93
(-0.01%) $962.50
(-0.04%) $0.932
(-0.10%) $10.98
(-0.05%) $0.797
(-0.01%) $91.12
Live Chart Being Loaded With Signals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)...
Stats | |
---|---|
Dagens volum | 3.00 |
Gjennomsnittsvolum | 4.22M |
Markedsverdi | 0.00 |
EPS | $0 ( 2021-07-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 59.23 |
ATR14 | $1.935 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Coughlin Christopher J | Sell | 42 347 | Common Stock, par value $.0001 per share |
2021-07-21 | Coughlin Christopher J | Sell | 2 294 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 706 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 343 | Option to Purchase Common Stock |
2021-07-21 | Sarin Aradhana | Sell | 120 253 | Common Stock, par value $.0001 per share |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 094 307 | Sell: 1 860 897 |
Volum Korrelasjon
Alexion Pharmaceuticals, Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
CREC | 0.977 |
LDHA | 0.976 |
PRSR | 0.976 |
MSDAU | 0.973 |
PWUP | 0.973 |
IXAQ | 0.972 |
CRZN | 0.972 |
IGTA | 0.97 |
VLAT | 0.97 |
AEAE | 0.969 |
10 Mest negative korrelasjoner | |
---|---|
FUV | -0.983 |
MESA | -0.979 |
MBIO | -0.979 |
JG | -0.977 |
MLKN | -0.975 |
RENT | -0.974 |
NXTC | -0.974 |
GERN | -0.974 |
ASRV | -0.973 |
CNTY | -0.973 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Alexion Pharmaceuticals, Korrelasjon - Valuta/Råvare
Alexion Pharmaceuticals, Økonomi
Annual | 2020 |
Omsetning: | $6.07B |
Bruttogevinst: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2020 |
Omsetning: | $6.07B |
Bruttogevinst: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2019 |
Omsetning: | $4.99B |
Bruttogevinst: | $4.60B (92.10 %) |
EPS: | $10.77 |
FY | 2018 |
Omsetning: | $4.13B |
Bruttogevinst: | $3.76B (90.94 %) |
EPS: | $0.348 |
Financial Reports:
No articles found.
Alexion Pharmaceuticals,
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.